Survival nomogram for patients with thymic squamous cell carcinoma, based on the SEER database and an external validation cohort

被引:0
|
作者
Guan, Yelan [1 ,2 ]
Xu, Feiqi [3 ]
Zheng, Shuai [4 ]
Gu, Xiaodong [3 ]
Sun, Yan [1 ,2 ]
机构
[1] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med HIM, Dept Clin Trial, Hangzhou 310022, Zhejiang, Peoples R China
[2] Wenzhou Med Univ, Zhejiang Canc Hosp, Postgrad Training Base Alliance, Hangzhou 310022, Zhejiang, Peoples R China
[3] Zhejiang Chinese Med Univ, Sch Clin Med 2, Hangzhou 310053, Zhejiang, Peoples R China
[4] Jinan Univ, Affiliated Hosp 1, Guangzhou 510630, Guangdong, Peoples R China
关键词
SEER; Nomogram; Thymic squamous cell carcinoma; Survival rate; External validation; POSTOPERATIVE RADIOTHERAPY; HISTOLOGIC CLASSIFICATION; RETROSPECTIVE ANALYSIS; EPITHELIAL TUMORS; PROGNOSIS; THYMOMA;
D O I
10.1007/s12672-023-00720-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
ObjectiveThis study aimed to construct a nomogram to effectively predict the 3 years and 5 years overall survival of patients with thymic squamous cell carcinoma (TSCC).MethodFrom 2000 to 2019, a total of 355 patients with TSCC were enrolled in our research from the Surveillance, Epidemiology, and End Results (SEER) database and used as the training cohort. 106 patients were included from the Zhejiang Cancer Hospital, for the external validation cohort. A nomogram was constructed based on the risk factors affecting prognosis using a Cox proportional hazards regression model. The discrimination and calibration of the nomogram were evaluated by C-index and curve of calibration. The two cohorts were divided into low-risk and high-risk subgroups based on the median risk score.ResultsAge (p = 0.002), stage (p = 0.003), surgery therapy (p < 0.001), and radiotherapy (p = 0.030) were the independent prognostic factors for overall survival and were incorporated in the prognostic model. The discrimination of the nomogram revealed a good prognostic accuracy and clinical applicability as indicated by C-index values of 0.696 (95% confidence interval [CI] 0.676-0.716) and 0.717 (95% CI 0.640-0.794) for the training cohort and external validation cohort, respectively. In addition, the two cohorts were divided into a high-risk group and a low-risk group according to the median risk score. Significant differences in overall survival were observed between the high-risk and low-risk groups in the training (p < 0.0001) and external validation cohort (p < 0.0001).ConclusionWe developed a nomogram to predict 3- and 5 year survival rate for TSCC. This nomogram provides a convenient and reliable tool for assessing the condition of patients with TSCC and assisting clinicians in making decisions.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Development and validation of a nomogram to predict overall survival of gastroenteropancreatic neuroendocrine carcinoma: a SEER database analysis
    Chen, Qishuang
    Guo, Yiying
    Wang, Zihan
    Chen, Xiaoying
    Tian, Chao
    Zheng, Jiabin
    Tan, Huangying
    TRANSLATIONAL CANCER RESEARCH, 2024, 13 (09)
  • [42] Development and validation of nomogram to predict risk of survival in patients with laryngeal squamous cell carcinoma
    Cui, Jie
    Wang, Liping
    Zhong, Waisheng
    Chen, Zhen
    Tan, Xiaojun
    Yang, Hong
    Chen, Jie
    Liu, Genglong
    BIOSCIENCE REPORTS, 2020, 40
  • [43] Development and Validation of Prognostic Nomogram for Young Patients with Hepatocellular Carcinoma (HCC): A Study Based on SEER Database
    Zhou, Changqing
    Zhu, Degang
    2023 7TH INTERNATIONAL CONFERENCE ON BIOMEDICAL ENGINEERING AND APPLICATIONS, ICBEA, 2023, : 15 - 22
  • [44] The development and validation of a nomogram for predicting brain metastases in lung squamous cell carcinoma patients: an analysis of the Surveillance, Epidemiology, and End Results (SEER) database
    Zhang, Jingya
    Xu, Jiali
    Jin, Shidai
    Gao, Wen
    Guo, Renhua
    Chen, Liang
    JOURNAL OF THORACIC DISEASE, 2021, 13 (01) : 270 - 281
  • [45] Predicting survival in patients with buccal cancer: A study based on SEER database and external validation in China
    Tan, Yongmei
    Huang, Guoxing
    Hu, Jintao
    Zhao, Shaoping
    Li, Yanyan
    Wen, Zhihui
    Wang, Liansheng
    Chen, Suling
    Chen, Rongxi
    Cao, Haotian
    Li, Jinsong
    CANCER MEDICINE, 2024, 13 (03):
  • [46] Deep learning model for predicting the survival of patients with primary gastrointestinal lymphoma based on the SEER database and a multicentre external validation cohort
    Feifan Wang
    Lu Chen
    Lihong Liu
    Yitao Jia
    Wei Li
    Lianjing Wang
    Jie Zhi
    Wei Liu
    Weijing Li
    Zhongxin Li
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 12177 - 12189
  • [47] Deep learning model for predicting the survival of patients with primary gastrointestinal lymphoma based on the SEER database and a multicentre external validation cohort
    Wang, Feifan
    Chen, Lu
    Liu, Lihong
    Jia, Yitao
    Li, Wei
    Wang, Lianjing
    Zhi, Jie
    Liu, Wei
    Li, Weijing
    Li, Zhongxin
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (13) : 12177 - 12189
  • [48] Survival nomograms for patients with retroperitoneal soft tissue sarcoma based on the SEER database and an external cohort
    Wu, Jing
    Zhang, Yunfei
    Yao, Gang
    Tuersunmaimaiti, Abudusalamu
    Azhati, Yilizhati
    Mamuti, Alimujiang
    Wen, Hao
    Tuxun, Tuerhongjiang
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (16) : 15013 - 15026
  • [49] Construction of a novel nomogram for predicting overall survival in patients with Siewert type II AEG based on LODDS: a study based on the seer database and external validation
    Yu, Xiaohan
    Bai, Chenglin
    Yu, Yang
    Guo, Xianzhan
    Wang, Kang
    Yang, Huimin
    Luan, Xiaodan
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [50] Survival nomograms for patients with retroperitoneal soft tissue sarcoma based on the SEER database and an external cohort
    Jing Wu
    Yunfei Zhang
    Gang Yao
    Abudusalamu Tuersunmaimaiti
    Yilizhati Azhati
    Alimujiang Mamuti
    Hao Wen
    Tuerhongjiang Tuxun
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 15013 - 15026